The ESMO and NCCN guidelines recommend atezolizumab (anti-PD-L1) combined with bevacizumab (anti-VEGF) as the first-line treatment for unresectable HCC (Benson et al., 2009; Reig et al., 2022). This evidence concerns the gene VEGFA and hepatocellular carcinoma.